|
|
|
|
|
|
|
|
|
|
|
14.04.26 - 12:15
|
Fosun Pharma FKC289 Injection Clinical Trial Approved (AAStocks)
|
|
|
Fosun Pharma (02196.HK) announced that its subsidiary Fosun Kairui has received approval from the National Medical Products Administration to conduct Phase I/II clinical trials of FKC289 injection for relapsed/refractory primary light-chain amyloidosis and relapsed/refractory membranous nephropathy. Fosun Kairui plans to carry o......
|
|
|
14.04.26 - 12:15
|
HENLIUS HLX05-N Phase I Clinical Trial Approved (AAStocks)
|
|
|
FOSUN PHARMA (02196.HK) announced that its subsidiary HENLIUS (02696.HK) has received approval from the National Medical Products Administration to conduct a Phase I clinical trial of HLX05-N (recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection) for the treatment of metastatic colorectal cancer. HENLIUS plan......
|
|
|
|
|
14.04.26 - 04:30
|
Research: M Stanley Raises PHARMARON TP to HKD31.5, Rating Overweight (AAStocks)
|
|
|
Morgan Stanley issued a research report updating the risk-reward profile of PHARMARON (03759.HK). The broker raised its target price from HKD31 to HKD31.5 and maintained an Overweight rating. In response to the groups 2025 results, the bank lifted its earnings forecasts for 2026 to 2030 by less than 1% to 3% to reflect higher r......
|
|
|
|
|
13.04.26 - 10:15
|
Research: M Stanley Trims 3SBIO TP to $34, Rating Overweight (AAStocks)
|
|
|
Morgan Stanley released a research report incorporating 3SBIO (01530.HK)'s 2025 results, and lowering its 2026-2028 revenue forecasts by 5%/ 7% / 6% each, due to reduced sales forecasts for 3SBIO's core commercialized product, TPIAO, and milestone payments, mainly affected by the depreciation of USD/ RMB. The broker also......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.04.26 - 09:30
|
China healthcare stocks outgain Hong Kong market as Middle East roils global investments (SCMP)
|
|
|
China's healthcare sector has been drawing offshore capital to Hong Kong-listed stocks as investors look for safe havens amid global volatility in commodities.
The Hang Seng Healthcare Index, tracking some of China's most innovative pharmaceutical companies including Akeso and Innovent Biologics, has surged about 13 per cent since March 23, outpacing the benchmark Hang Seng Index's about 6 per cent gain over the same period.
“Although the Middle East conflict has created a lot of uncertainty and......
|
|
|
10.04.26 - 02:03
|
Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases (PR Newswire)
|
|
|
SAN FRANCISCO and SUZHOU, China, April 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
